Combination Therapy with Fenofibrate and Statins

Introduction to Combination Therapy

• The American College of Cardiology recommends adding fenofibrate to statin therapy for patients with persistently elevated triglycerides (≥200 mg/dL) and low HDL-C despite statin therapy, although cardiovascular outcome benefits remain unproven 1, 2, 3

Patient Selection for Combination Therapy

• The American College of Cardiology suggests that patients with triglycerides ≥204 mg/dL and HDL-C ≤40 mg/dL may derive cardiovascular benefit from fenofibrate-statin combination therapy, though evidence is limited 1, 2
• Patients with severe hypertriglyceridemia (>500 mg/dL) may benefit from fenofibrate-statin combination therapy to reduce pancreatitis risk 3

Mandatory Monitoring Protocol

• The American College of Cardiology recommends monitoring renal function, including serum creatinine and eGFR, before initiating fenofibrate-statin combination therapy and periodically thereafter 3
• The American Heart Association suggests monitoring hepatic function, including ALT, AST, and total bilirubin, before initiating fenofibrate-statin combination therapy 6, 7

Dosing Adjustments Based on Renal Function

• The American College of Cardiology recommends reducing the dose of fenofibrate to 54 mg daily in patients with eGFR 30-59 mL/min/1.73 m² 3
• The National Kidney Foundation suggests discontinuing fenofibrate immediately if eGFR drops persistently to <30 mL/min/1.73 m² during treatment 3

Statin Selection for Combination Therapy

• The American College of Cardiology recommends using pravastatin as the first choice for combination with fenofibrate due to its low drug interaction potential 8, 9
• The American Heart Association suggests using fluvastatin as an alternative to pravastatin, as it uses CYP2C9 and avoids CYP3A4 interactions 2

Expected Lipid Effects

• The American College of Cardiology reports that adding fenofibrate to statin therapy can decrease triglycerides by 23-59% (mean reduction ~38%) 1, 2
• The American Heart Association notes that HDL-C can increase by 1-2 mg/dL (11-17% increase) with fenofibrate-statin combination therapy 6, 7

Special Population Considerations

• The American College of Cardiology recommends using extreme caution when prescribing fenofibrate-statin combination therapy to elderly patients due to higher myopathy risk 6, 7
• The American Diabetes Association suggests that women with well-controlled diabetes may have higher cardiovascular event rates with fenofibrate-statin combination therapy compared to statin alone 1, 2

Alternative Approaches

• The American College of Cardiology suggests considering alternative approaches, such as adding niacin to statin therapy or using high-dose omega-3 fatty acids, if fenofibrate-statin combination therapy is not appropriate 6, 7